Incorrect password
evipedia.ai Suggest Edit

Low-Dose Naltrexone for Health & Longevity

Evidence Review created on 04/28/2026 using AI4L / Opus 4.7

Also known as: LDN, Low Dose Naltrexone, Naltrexone (low-dose)

Motivation

Low-dose naltrexone is the off-label use of naltrexone — a medication originally approved for opioid and alcohol use disorders — at roughly one-tenth of its standard dose. At these low doses, the molecule appears to act less as a classic opioid blocker and more as a modulator of immune cells in the brain and body, with downstream effects on inflammation and pain processing.

The concept emerged in the mid-1980s from the clinical practice of New York neurologist Bernard Bihari and has accumulated a heterogeneous evidence base spanning fibromyalgia, Crohn’s disease, and more recently long COVID. Very low cost, long-expired patents, decades of post-marketing safety data, and a plausible anti-inflammatory mechanism have made it a frequently discussed candidate within the longevity community, although no large pivotal trial has tested it for healthspan or lifespan in humans and the available randomized data remain mixed.

This review examines what is currently known and unknown about low-dose naltrexone as a health and longevity intervention, including its proposed mechanisms, clinical outcomes across approved and off-label uses, the safety profile and contraindications, and the ongoing trials that may shape its place in longevity medicine.

Benefits - Risks - Protocol - Conclusion

This section highlights resources that give a high-level overview of low-dose naltrexone’s mechanisms, clinical applications, and emerging relevance to longevity.

  • Low-Dose Naltrexone (LDN) as a Treatment for Autoimmune Disease - Chris Kresser

    Long-form podcast transcript covering LDN (low-dose naltrexone) history with Bernard Bihari, mechanism via opioid receptor antagonism and microglial modulation, the conditions it has been studied for, immune-modulating and anti-inflammatory effects, and practical clinical considerations including dosing and how to find a prescriber.

  • #345 - Chronic pain: pathways, treatment, and the path to physical and psychological recovery - Peter Attia

    Episode of The Drive podcast featuring Stanford pain medicine expert Sean Mackey. Discusses LDN’s role in chronic pain treatment, its proposed mechanism via toll-like receptor 4 antagonism on microglia, possible brain benefits for mild cognitive impairment, and its growing acceptance in mainstream pain medicine.

  • How to Control Your Sense of Pain & Pleasure - Andrew Huberman

    Episode covering the neuroscience of pain and pleasure pathways. Huberman highlights low-dose naltrexone’s reported efficacy in fibromyalgia through its action on toll-like receptor 4 on glial cells, and frames it as a treatment to discuss with a physician for chronic widespread pain.

  • The Use of Low-Dose Naltrexone (LDN) as a Novel Anti-Inflammatory Treatment for Chronic Pain - Younger et al., 2014

    Foundational narrative review from Stanford University synthesizing the evidence for LDN’s central anti-inflammatory mechanism via microglial modulation, with clinical findings in fibromyalgia, Crohn’s disease, and multiple sclerosis, plus practical usage guidance and safety considerations.

  • LDN Calling: Low-Dose Naltrexone Could Be Just the Ticket - Eleanor Garth

    Accessible overview connecting LDN to the longevity and healthspan conversation, featuring expert commentary from clinician Sajad Zalzala on dosing, mechanisms, endorphin upregulation, and LDN’s potential as a geroprotective agent with a favorable side-effect profile.

No directly relevant content addressing LDN was identified from Rhonda Patrick (foundmyfitness.com) or Life Extension Magazine (lifeextension.com) despite searches on each platform and the broader web; this likely reflects editorial focus on supplements and food-derived compounds rather than off-label prescription drugs.

Grokipedia

Low-dose naltrexone

Provides a comprehensive encyclopedic overview of LDN’s pharmacology, the dose-dependent divergence between standard-dose and low-dose mechanisms, the clinical evidence in fibromyalgia, Crohn’s disease, multiple sclerosis, complex regional pain syndrome, autoimmune skin disorders, long COVID, and the safety profile.

Examine

No dedicated article for low-dose naltrexone or naltrexone was found on Examine.com. Examine.com does not typically cover prescription medications, and LDN is an off-label use of the prescription drug naltrexone.

ConsumerLab

No dedicated article for low-dose naltrexone or naltrexone was found on ConsumerLab.com. ConsumerLab does not typically cover prescription medications, and LDN is an off-label use of the prescription drug naltrexone.

Systematic Reviews

This section lists the highest-quality systematic reviews and meta-analyses for low-dose naltrexone identified on PubMed.

Mechanism of Action

Low-dose naltrexone’s effects appear to operate through several interrelated mechanisms that are distinct from naltrexone’s conventional sustained opioid receptor blockade at the standard 50 mg dose:

  • Transient opioid receptor blockade and endorphin upregulation: At 1-5 mg taken at bedtime, LDN briefly blocks mu-opioid receptors (the brain’s main receptors for endorphins and opioid drugs) for approximately 4-6 hours. This transient blockade is hypothesized to trigger compensatory upregulation of endogenous opioid production — particularly beta-endorphin and met-enkephalin — and an increase in opioid receptor density. By the following morning, the drug has cleared and the elevated endorphin levels act on the upregulated receptors, producing enhanced pain modulation, mood effects, and immune regulation.

  • TLR4 (toll-like receptor 4, an immune-cell sensor that triggers inflammatory responses) antagonism on microglia: LDN antagonizes TLR4 on microglia (the immune cells of the central nervous system) and other immune cells. When chronically activated, microglia release proinflammatory cytokines (cell-signaling proteins that drive inflammation) including IL-6 (interleukin-6, a key inflammatory cytokine) and TNF-alpha (tumor necrosis factor alpha, another central inflammatory mediator). Suppressing this activation reduces central and systemic inflammation. This mechanism appears to be opioid-receptor-independent and is consistent with stereoisomer studies showing both (+) and (-) naltrexone enantiomers can act at TLR4 even though only the (-) enantiomer binds opioid receptors.

  • OGF-OGFr axis modulation (opioid growth factor / opioid growth factor receptor axis, a regulatory system that controls cell proliferation): LDN’s transient blockade of OGFr leads to compensatory upregulation of OGF (met-enkephalin), which modulates cell growth, tissue repair, and immune cell activity. This mechanism is most often invoked for LDN’s investigational roles in cancer and wound healing.

  • TRPM3 ion channel function in natural killer cells: Recent electrophysiology work (Sasso et al., 2025) found that natural killer cells from long COVID patients have impaired TRPM3 (transient receptor potential melastatin 3, an ion channel that lets calcium into immune cells) function and that LDN treatment restores channel current to that of healthy controls, providing a mechanistic anchor for LDN’s reported benefit in post-viral fatigue syndromes.

  • Geroprotective signaling (preclinical): Li et al. (2024) showed that low — but not high — naltrexone concentrations extend healthspan and lifespan in Caenorhabditis elegans via SKN-1 (the worm ortholog of NRF2 (nuclear factor erythroid 2-related factor 2, a master regulator of antioxidant defense and longevity in mammals)), with associated upregulation of innate immune gene expression and oxidative stress response. Whether the same pathway is engaged in humans is not yet established.

Competing mechanistic interpretations have been advanced. Older clinical literature emphasized the rebound endorphin model as the primary explanation; recent reviews increasingly favor TLR4-mediated glial modulation, with the endorphin effect re-cast as a downstream or parallel phenomenon. Both descriptions converge on the same observable outcomes — reduced pain processing and dampened inflammation — but they differ in implications for dose selection (timing-sensitive in the endorphin-rebound model, less so in the TLR4 model).

Pharmacological properties:

  • Half-life: Plasma half-life of naltrexone is approximately 4 hours; its primary active metabolite, 6-beta-naltrexol, has a half-life of approximately 12 hours
  • Selectivity: Competitive antagonist at mu, kappa, and (to a lesser extent) delta opioid receptors; at LDN doses, occupancy is partial and time-limited
  • Tissue distribution: Crosses the blood-brain barrier; volume of distribution is large (~1,350 L), reflecting extensive tissue distribution
  • Metabolism and excretion: Primarily hepatic, via dihydrodiol dehydrogenase (a liver enzyme that reduces naltrexone to its active metabolite 6-beta-naltrexol) to 6-beta-naltrexol; minor pathways involve CYP (cytochrome P450, a family of liver enzymes that metabolize most drugs) enzymes including CYP2D6 (handles many psychotropic drugs and beta-blockers; activity varies markedly by genotype) and CYP2C9 (handles warfarin, NSAIDs (non-steroidal anti-inflammatory drugs such as ibuprofen and naproxen), and several antidiabetic drugs); excretion is primarily renal
  • Bioavailability: Approximately 5-40% oral bioavailability due to extensive first-pass metabolism; clinical effect is driven mainly by the active metabolite 6-beta-naltrexol

Historical Context & Evolution

Naltrexone was first synthesized in 1963 by Endo Laboratories (later acquired by DuPont) and received FDA (Food and Drug Administration, the U.S. regulatory agency for drugs and medical devices) approval in 1984 for opioid use disorder at 50 mg daily. Approval for alcohol use disorder followed in 1994. At these standard doses, naltrexone provides sustained competitive blockade of opioid receptors to prevent the reinforcing effects of opioids and alcohol.

The concept of low-dose naltrexone originated with Bernard Bihari, a neurologist in New York City, in the mid-1980s. While treating patients with opioid addiction, Bihari observed unexpected immune-enhancing effects at very low naltrexone doses. He subsequently used approximately 3 mg nightly in patients with HIV/AIDS and cancer and reported improvements in immune function and quality of life. His clinical observations spawned a grassroots community of patients and prescribers; Bihari’s work was never published as a formal randomized trial during his lifetime, and the historical evidence base remains characterized by his published findings, those of his collaborators, and a long tail of small investigator-initiated studies.

Through the 1990s and 2000s, interest expanded to autoimmune and inflammatory conditions, with early clinical work in multiple sclerosis, Crohn’s disease, and fibromyalgia. Jill Smith at Penn State published a pilot study in 2007 showing that LDN induced clinical remission in 67% (later commonly described as 89% with response) of Crohn’s disease patients, followed by a randomized controlled trial in 2011. Jarred Younger at Stanford then conducted controlled studies in fibromyalgia and proposed microglial modulation via TLR4 as the central mechanism, broadening interest beyond the original endorphin-rebound model.

LDN has remained off-label because naltrexone’s patent expired long before low-dose applications were investigated, removing the financial incentive for any pharmaceutical company to fund the large registration trials needed for a new FDA indication. Its evidence base has grown primarily through investigator-initiated small trials, clinical case series, retrospective real-world cohorts, and a dedicated patient-advocacy ecosystem including the LDN Research Trust and clinics such as AgelessRx. The most recent academic developments have come from work in fibromyalgia (multiple meta-analyses 2023-2025), long COVID and ME/CFS (myalgic encephalomyelitis/chronic fatigue syndrome, a debilitating condition characterized by profound fatigue and post-exertional malaise) (mechanistic studies and protocol publications), and a 2024 C. elegans lifespan study by Li et al. that placed LDN explicitly within the geroscience conversation. Several conflicts of interest are visible in this evidence ecosystem: many of the most prominent longevity-oriented studies and case reports come from clinician-investigators affiliated with telehealth providers (notably AgelessRx) that prescribe and dispense LDN.

Expected Benefits

A dedicated search was performed across PubMed, recent narrative and systematic reviews, clinical trial registries, and clinician-authored summaries (Younger 2014, Kresser, Attia, Huberman, AgelessRx, LDN Research Trust) to identify the full benefit profile claimed for low-dose naltrexone in pain, autoimmune, post-viral, and longevity contexts.

High 🟩 🟩 🟩

Chronic Pain Reduction in Fibromyalgia ⚠️ Conflicted

Multiple small RCTs and four recent meta-analyses (2024-2025) examine LDN for fibromyalgia. The Vatvani et al. (2024) meta-analysis of 4 RCTs (222 patients) reported a significant LDN-versus-placebo reduction in pain scores (mean difference -0.86, p < 0.001) and improved pressure pain threshold. The Hegde et al. (2025) meta-analysis of 7 RCTs found LDN superior to placebo specifically for fibromyalgia pain (Cohen’s d = -0.34, p = 0.019). However, the Ologunowa et al. (2025) meta-analysis of 8 trials found that within-group improvements (SMD -1.03) did not exceed placebo-group improvements when pooled (between-group SMD non-significant), indicating substantial heterogeneity and a meaningful placebo response in this population.

Magnitude: Mean pain-score reduction of 0.86 points (Vatvani 2024); Cohen’s d = -0.34 versus placebo (Hegde 2025); within-group SMD of -1.03 from baseline (Ologunowa 2025).

Medium 🟩 🟩

Crohn’s Disease Symptom Improvement

The 2018 Cochrane review (Parker et al.) found significantly higher 70-point clinical response rates (83% versus 38%, RR = 2.22) and endoscopic response (72% versus 25%, RR = 2.89) with LDN compared with placebo in adult Crohn’s disease, although clinical remission did not reach statistical significance and the overall evidence quality was rated low due to sparse data. Smith et al. (2007, 2011) demonstrated clinical response in approximately 78% and remission in approximately 33% of LDN-treated patients in earlier open-label and randomized work.

Magnitude: 70-point clinical response in 83% of LDN-treated patients versus 38% on placebo; endoscopic response in 72% versus 25% on placebo.

Immune Modulation and Anti-Inflammatory Effects

LDN upregulates endogenous opioid production (beta-endorphin, met-enkephalin), enhances natural killer (NK) cell activity, and increases regulatory T cell function. The Sasso et al. (2025) electrophysiology work showed that LDN restores TRPM3 ion-channel current in NK cells from long COVID patients to that of healthy controls, providing a concrete cellular readout. ESR (erythrocyte sedimentation rate, a blood test that measures inflammation) reductions have been reported in fibromyalgia trials, and the TLR4-mediated suppression of proinflammatory cytokines is consistent across animal and ex vivo human work, with relevance to inflammaging (the chronic low-grade inflammation associated with biological aging).

Magnitude: Significant ESR reductions reported in fibromyalgia trials; restoration of NK-cell TRPM3 currents to healthy-control levels in long COVID; specific cytokine reductions not yet quantified in adequately powered human LDN-specific studies.

Post-COVID Fatigue Improvement

Multiple uncontrolled and small controlled studies have examined LDN for long COVID symptoms. The AgelessRx-sponsored Isman et al. (2024) prospective interventional study (n=36) — note that AgelessRx is a telehealth provider that prescribes and dispenses LDN, a direct commercial interest in positive findings — reported significant improvements in SF-36 (a standardized quality-of-life questionnaire) total score (36.5 to 52.1, p < 0.0001) and Chalder fatigue (25.9 to 17.4, p < 0.0001) over 12 weeks of LDN combined with NAD+ (nicotinamide adenine dinucleotide, a coenzyme essential for cellular energy production) iontophoresis patches; 52% of participants met responder criteria. The Sasso et al. (2025) mechanistic study supports a cellular rationale via TRPM3 restoration. The Jagannathan et al. (2025) post hoc analysis of the STOP-PASC trial (n=155) found a higher proportion of LDN users in the worsening trajectory groups; this is interpretable as a confounding-by-indication signal (sicker patients were more likely to be using LDN at baseline) rather than evidence that LDN caused worsening, but it underscores the limitations of uncontrolled data. The ongoing LIFT trial (NCT06366724; n=160) will provide controlled evidence.

Magnitude: SF-36 increase from 36.5 to 52.1 (p < 0.0001) and Chalder fatigue reduction from 25.9 to 17.4 (p < 0.0001) over 12 weeks in the AgelessRx LDN+NAD+ pilot; 52% responder rate.

Multiple Sclerosis Symptom Stabilization

Open-label and small controlled studies (Cree et al., 2010; Sharafaddinzadeh et al., 2010; Ludwig et al., 2016) report improved mental-health composite scores on the SF-36, stable EDSS (Expanded Disability Status Scale, a method for quantifying neurologic disability in multiple sclerosis) over more than 2 years, and improved fatigue measures with LDN at 4.5 mg/day. The studies are small, mostly without modern disease-modifying therapy comparators, and some show no benefit on quality-of-life subscales, so the signal remains intriguing rather than definitive. Larger controlled trials are absent.

Magnitude: Stable EDSS over more than 2 years in observational cohorts; improvement in SF-36 mental-health composite of 6-8 points in the Cree pilot.

Low 🟩

Complex Regional Pain Syndrome and Neuropathic Pain

Case series and small open-label work suggest LDN reduces pain and improves function in complex regional pain syndrome (CRPS) and other neuropathic pain conditions. The Soin et al. (2021) systematic review of CRPS literature found generally favorable signals but rated the evidence as limited. Active trials, including NCT02502162, NCT06306157, and NCT06723561 for spinal cord injury neuropathic pain, are underway and may strengthen or weaken this signal.

Magnitude: Not quantified in available studies.

Lichen Planopilaris and Frontal Fibrosing Alopecia (Scalp Inflammation)

The Bai et al. (2025) systematic review identified 7 small studies in cicatricial alopecias (a group of inflammatory hair-loss conditions in which the hair follicle is permanently destroyed and replaced by scar tissue) — including lichen planopilaris (an inflammatory scalp condition that destroys hair follicles and causes patchy hair loss with redness and itching) and frontal fibrosing alopecia (a related scarring hair-loss condition that progressively recedes the frontal and temporal hairline) — reporting reduced scalp pruritus and inflammation in a majority of patients with low-dose naltrexone, generally in the context of multimodal treatment. Evidence quality is low (open-label, small samples), and effects on hair regrowth are inconsistent.

Magnitude: Symptomatic improvement (pruritus, erythema) reported in approximately 60-80% of treated patients across small case series; not quantified by formal effect size.

Mood and Well-Being Enhancement

Endorphin upregulation from LDN may improve mood, energy, and overall well-being. Clinical reports and observational cohorts describe improvements in depressive symptoms, particularly in patients with comorbid chronic pain or autoimmune disease. Huberman has highlighted the relationship between endorphin systems and mood. No adequately powered placebo-controlled trial has specifically targeted depression as a primary endpoint with LDN.

Magnitude: Not quantified in available studies.

The Liubchenko et al. (2021) systematic review of cell-culture, animal-model, and human studies described preclinical evidence for naltrexone’s dose-dependent effects on tumor proliferation — high continuous doses promoting and low intermittent doses opposing tumorigenesis — but human evidence is limited to case reports and small case series in pancreatic, colorectal, and ovarian cancers. The active NCT07224009 study in fatigue during androgen-deprivation therapy for prostate cancer will provide additional human data. Memorial Sloan Kettering and other major cancer centers note that larger trials are needed before LDN can be recommended for cancer treatment.

Magnitude: Not quantified in available studies.

Speculative 🟨

Slowing of Biological Aging and Healthspan Extension

The Li et al. (2024) iScience study showed dose-dependent lifespan extension in C. elegans at low (2.5-5 micromolar) but not high (50-100 micromolar) naltrexone concentrations, mediated by SKN-1 (the worm ortholog of mammalian NRF2) and associated with enhanced innate immune gene expression and oxidative stress response. AgelessRx investigators (Britton et al., 2025) — again noting AgelessRx’s commercial interest in LDN-favorable findings as a telehealth LDN provider — have published a case report of unexpectedly increased lumbar bone mineral density (15.9% over two years) in a 52-year-old woman taking rapamycin and LDN. The combined anti-inflammatory, immune-modulating, and potential NRF2-activating properties align with multiple hallmarks of aging, but no human trial has used aging biomarkers or longevity endpoints as primary outcomes. The combination gerotherapeutic trial NCT07475546 is the first attempt to study LDN within a longevity protocol.

Neuroprotection

Preclinical and mechanistic evidence suggests LDN may protect against neurodegeneration through suppression of microglial overactivation — a recognized contributor to Alzheimer’s disease, Parkinson’s disease, and ALS (amyotrophic lateral sclerosis, a progressive motor neuron disease). Kresser has highlighted research linking chronic microglial activation to neurodegenerative disease; Attia’s podcast (#345 with Sean Mackey) discussed possible brain benefits for mild cognitive impairment. Direct human cognitive-outcome data with LDN are absent.

Weight Management Support

LDN may contribute to modest weight management through improved energy levels, reduced systemic inflammation, and potential appetite regulation via endorphin modulation. A retrospective AgelessRx cohort reports modest weight reduction in LDN users. The standard-dose naltrexone-bupropion combination (Contrave) has far stronger evidence for weight loss, and LDN’s independent effect on weight is poorly characterized; an active trial (NCT07092618) is examining LDN among other interventions for weight maintenance after GLP-1 (glucagon-like peptide-1, a gut hormone that suppresses appetite and lowers blood glucose) discontinuation.

Benefit-Modifying Factors

  • Genetic polymorphisms: Variants in OPRM1 (the gene encoding the mu-opioid receptor, the primary target of endorphins and opioid drugs) — particularly the A118G polymorphism — may influence individual response by altering receptor binding affinity and endorphin signaling. CYP2D6 polymorphisms can affect naltrexone metabolism, potentially altering LDN’s effective duration; ultrarapid metabolizers may experience attenuated benefit, while poor metabolizers may experience prolonged effect at any given dose.

  • Baseline biomarker levels: Individuals with elevated inflammatory markers (CRP (C-reactive protein, a blood marker of systemic inflammation), ESR, IL-6) or documented low endogenous opioid tone may experience more pronounced benefits from LDN’s anti-inflammatory and endorphin-upregulating mechanisms. Those with already-normal inflammatory profiles may see more subtle effects; this matters most for the speculative longevity use case in otherwise healthy adults.

  • Sex-based differences: Women comprise the majority of participants in fibromyalgia and autoimmune trials of LDN, reflecting the higher prevalence of these conditions in females. Some clinical observations suggest women may respond more robustly to LDN for pain conditions; whether this reflects population bias or a true sex-based pharmacological difference is unresolved.

  • Pre-existing health conditions: Patients with documented autoimmune disease, chronic pain syndromes, or chronic inflammatory states have the largest evidence base supporting benefit. Healthy adults seeking LDN solely as a longevity intervention have the weakest direct evidence to support benefit.

  • Age: Older adults (55+) may have more to gain from LDN’s anti-inflammatory and immune-modulating actions, given the prominence of inflammaging and immune senescence (the age-related decline in immune function). Older adults may also have somewhat altered naltrexone metabolism and should start at lower doses.

  • Concomitant gerotherapeutics: Preliminary case-report evidence (Britton et al., 2025) and the design of NCT07475546 suggest LDN may interact additively with rapamycin and other gerotherapeutics, but this remains hypothesis-generating.

Potential Risks & Side Effects

A dedicated search was performed across the FDA naltrexone prescribing information, drugs.com, Mayo Clinic, the Bolton et al. (2019) safety meta-analysis (89 RCTs, 11,194 participants), and recent LDN-specific systematic reviews. The safety profile at low doses is generally favorable; the most clinically important risks are the absolute opioid contraindication and short-term tolerability events, with theoretical long-term concerns that remain under-characterized.

High 🟥 🟥 🟥

Vivid Dreams and Sleep Disturbance

Sleep disturbance and vivid or unusual dreams are the most consistently reported side effects of LDN, reported significantly more often with LDN than placebo in the Vatvani et al. (2024) and Hegde et al. (2025) meta-analyses. The effect is attributed to LDN’s transient blockade of opioid receptors during the night, altering REM (rapid eye movement, the sleep stage associated with dreaming) sleep architecture. Symptoms typically diminish within 1-2 weeks of initiation or with morning dosing.

Magnitude: Reported in approximately 8-15% of users in clinical trials; significantly higher with LDN than placebo in pooled analysis; typically transient.

Precipitated Opioid Withdrawal in Opioid-Exposed Individuals

LDN can precipitate severe and rapid opioid withdrawal in anyone with recent opioid exposure (prescription or illicit), including buprenorphine and methadone. This is a class effect of any opioid antagonist (a drug that binds to opioid receptors and blocks their activation) and is the single most important acute safety issue for LDN. Symptoms can include severe agitation, dysphoria, vomiting, diarrhea, autonomic instability, and rarely cardiovascular events. Patients must be opioid-free for at least 7-10 days (3-7 for short-acting opioids; 10-14 for long-acting agents such as buprenorphine and methadone) before initiation.

Magnitude: Severe and immediate when triggered; frequency depends entirely on prescribing diligence and patient disclosure of opioid use.

Medium 🟥 🟥

Gastrointestinal Symptoms

Nausea, abdominal discomfort, and diarrhea are reported in clinical trials, with rates generally comparable to placebo in the Cochrane review of LDN in Crohn’s disease. Nausea is more common during the first 1-2 weeks of use and is generally self-limiting.

Magnitude: Mild nausea in approximately 5-10% of users during the first week; typically self-limiting.

Headache

Headache is reported across multiple LDN trials. The Bolton et al. (2019) safety meta-analysis of 89 RCTs across all naltrexone doses found only six marginally significant adverse-event categories, all of mild severity, with headache among them. Headache appears to be dose-related and more common during initiation.

Magnitude: Mild and transient; comparable to or modestly above placebo rates in controlled trials.

Temporary Symptom Flare at Initiation

Some patients experience temporary worsening of their underlying symptoms during the first 1-2 weeks of LDN therapy (“flare”), believed to relate to the initial opioid receptor blockade before compensatory endorphin upregulation takes effect. The phenomenon is well-described in clinical practice and patient-reported outcomes data but poorly characterized in controlled studies; it is one driver of the worsening trajectory association seen in the Jagannathan et al. (2025) STOP-PASC analysis, although that signal cannot distinguish flare from confounding-by-indication.

Magnitude: Not quantified in available studies; commonly reported in clinical case series.

Low 🟥

Mood Changes

Anxiety, irritability, and rarely depressive symptoms have been reported, particularly in individuals with pre-existing mood disorders. The naltrexone prescribing information carries a general warning regarding depression and suicidality, although that warning primarily references the standard 50 mg dose used for addiction treatment. At LDN doses, mood-related side effects appear uncommon and have not been reliably distinguished from placebo in pooled analyses.

Magnitude: Not quantified in available studies; consistently below 5% in trial reports at LDN doses.

Hepatotoxicity Concern

Standard-dose naltrexone (50 mg+) carries a boxed warning for hepatotoxicity based on early dose-finding trials showing transaminase elevations at doses of 300 mg. At LDN doses (1-5 mg) there are no documented cases of clinical liver injury, and the Bolton et al. (2019) safety meta-analysis across all naltrexone doses found no increased risk of serious adverse events versus placebo. The boxed warning nonetheless creates warranted caution for patients with active hepatic disease.

Magnitude: No documented cases of hepatotoxicity at LDN doses (1-5 mg); the boxed warning applies to doses well above the LDN range.

Compounded LDN preparations vary in fillers, slow-release matrices, and excipients; some compounding pharmacies have used calcium carbonate or other fillers that interfere with absorption. Individual reports describe rashes or local reactions to specific excipients rather than to naltrexone itself.

Magnitude: Not quantified in available studies; depends heavily on compounding pharmacy practices.

Speculative 🟨

Long-Term Immunomodulatory Unknowns

While LDN’s immune-modulating effects are framed as beneficial, long-term consequences of chronic immune modulation in healthy adults remain hypothetical. Younger et al. (2014) noted that suppression of immune-system parameters could in principle raise the risk of infections or alter immunosurveillance, although no such effects have been reported at any naltrexone dose to date.

Confounding-by-Indication in Real-World Long COVID Cohorts

The Jagannathan et al. (2025) post hoc analysis of the STOP-PASC trial reported that worsening-trajectory groups had a higher proportion of LDN users. The most parsimonious interpretation is that sicker patients were more likely to have started LDN before the trial; nonetheless, the absence of randomized evidence in long COVID and ME/CFS leaves open the small possibility that LDN may not benefit, or could worsen, certain post-viral phenotypes. The LIFT trial (NCT06366724) and dose-finding study NCT07285473 will help resolve this.

Effects in Combination with Other Gerotherapeutics

The Britton et al. (2025) case report of unexpectedly increased bone mineral density on rapamycin + LDN is an isolated observation. Combined effects on immune function, mTOR (mechanistic target of rapamycin, a central regulator of cellular growth and aging) signaling, and cancer surveillance are theoretically plausible in either direction and have not been formally studied.

Risk-Modifying Factors

  • Genetic polymorphisms: CYP2D6 poor metabolizers may have prolonged exposure to the active 6-beta-naltrexol metabolite, potentially extending receptor blockade and increasing side-effect frequency, while ultrarapid metabolizers may clear LDN too quickly for therapeutic effect. CYP2C9 polymorphisms are also relevant given the meta-analysis-level signal of modestly higher adverse events with LDN versus placebo.

  • Baseline biomarker levels: Individuals with elevated baseline ALT (alanine aminotransferase, a liver enzyme used to assess hepatic health) or AST (aspartate aminotransferase, another liver enzyme) may be at theoretically higher risk for hepatic complications, although no LDN-specific cases have been documented; the boxed warning for naltrexone applies primarily to the 50 mg+ dose range.

  • Sex-based differences: Women may be slightly more susceptible to vivid dreams and sleep disturbance based on clinical reports, although this has not been formally quantified by sex. Hormonal fluctuations may influence endorphin dynamics and thus LDN response.

  • Pre-existing health conditions: Patients with pre-existing mood disorders (depression, anxiety) should be monitored more closely when initiating LDN. Those with active hepatic disease or known opioid use disorder should use LDN only with specialist supervision.

  • Age: Older adults may have reduced hepatic clearance of naltrexone and its metabolites, potentially extending receptor blockade. Clinicians prescribing for individuals over 65 commonly start at lower doses (0.5-1.5 mg) and titrate more slowly.

  • Concomitant medications: Concomitant opioid agonists (drugs that bind to and activate opioid receptors — prescription, illicit, or partial agonists (drugs that activate the receptor only weakly) such as buprenorphine and methadone) constitute the main pharmacologic risk modifier — they convert LDN from a generally well-tolerated agent into one capable of precipitating severe withdrawal.

Key Interactions & Contraindications

  • Opioid agonists (prescription): Absolute contraindication with any full or partial mu-opioid agonist, including codeine, hydrocodone, oxycodone, morphine, hydromorphone, oxymorphone, fentanyl, methadone, and buprenorphine. Severity: absolute contraindication. Clinical consequence: severe precipitated withdrawal. Patients must be opioid-free for at least 7-10 days (longer for long-acting agents) before initiation; a naloxone challenge can confirm clearance.

  • Tramadol and tapentadol (atypical opioids with mixed mechanisms): Same class precaution as full opioid agonists; contraindicated. Severity: absolute contraindication.

  • Over-the-counter opioid-containing or opioid-active products: Loperamide (an antidiarrheal with peripheral opioid activity), dextromethorphan (in some cough suppressants), and diphenoxylate (in some anti-diarrheals such as Lomotil) should be avoided or used with caution. Severity: caution to absolute contraindication depending on the product. Clinical consequence: variable, ranging from precipitated withdrawal to attenuation of symptom relief.

  • Immunosuppressants (e.g., methotrexate, mycophenolate, calcineurin inhibitors such as tacrolimus and cyclosporine): Theoretical interaction since LDN modulates immune function; concurrent use should be approached with caution and specialist oversight in transplant or severe autoimmune contexts. Severity: caution. Clinical consequence: unpredictable net immune effect.

  • CYP2D6 substrates and inhibitors (e.g., paroxetine, fluoxetine, bupropion, many beta-blockers such as metoprolol, antipsychotics such as risperidone): Preclinical data show naltrexone interacts modestly with CYP2D6 and CYP2C9. Severity: caution. Clinical consequence: small theoretical changes in exposure with narrow-therapeutic-index drugs; monitor.

  • CYP2C9 substrates (e.g., warfarin, NSAIDs, certain antidiabetic drugs): Severity: caution. Clinical consequence: small theoretical changes in exposure with narrow-therapeutic-index drugs.

  • Tamoxifen: Memorial Sloan Kettering notes uncertainty about whether LDN may affect tamoxifen activity; caution is warranted in breast cancer patients on this therapy. Severity: caution. Clinical consequence: potential reduction in tamoxifen anticancer efficacy.

  • Supplements with immunostimulatory properties (echinacea, astragalus, AHCC (active hexose correlated compound, a mushroom-derived immunomodulatory extract)): Theoretical additive immunomodulatory effects; clinical significance is unknown. Severity: monitor. Clinical consequence: unpredictable net immune effect or amplified immunomodulation.

  • Other gerotherapeutics (rapamycin, metformin, acarbose, urolithin A): No direct pharmacokinetic interactions documented; combined immunologic and metabolic effects are theoretically possible and form the rationale for the NCT07475546 combination trial. Severity: monitor. Clinical consequence: theoretically additive or unpredictable effects on immune function and cancer surveillance.

Populations who should avoid low-dose naltrexone:

  • Anyone with current or recent (within 7-14 days) opioid use — including prescription, illicit, and opioid-containing OTC (over-the-counter) products (absolute contraindication)
  • Anyone with current opioid use disorder not yet detoxified (absolute contraindication)
  • Patients on chronic buprenorphine or methadone without specialist transition (absolute contraindication for the standard LDN protocol)
  • Patients with acute hepatitis or hepatic decompensation (Child-Pugh Class C, the most severe category of cirrhosis) (caution; specialist consultation needed)
  • Pregnant or breastfeeding women (insufficient safety data)
  • Patients with known hypersensitivity to naltrexone or excipients in the compounded preparation (absolute contraindication)
  • Patients within 48-72 hours of planned surgery requiring opioid analgesia (LDN must be discontinued before procedures to allow adequate opioid analgesic response)

Risk Mitigation Strategies

  • Verify opioid clearance before initiation: Confirm complete abstinence from all opioid agonists and partial agonists for at least 7-10 days (3-7 days for short-acting opioids; 10-14 days for long-acting agents such as buprenorphine and methadone). A urine drug screen or formal naloxone challenge can confirm clearance. Mitigates the most acute and severe risk: precipitated opioid withdrawal.

  • Gradual dose titration: Start at 0.5-1.5 mg nightly and increase by 0.5-1.0 mg every 1-2 weeks until reaching the target dose (typically 4.5 mg). Mitigates frequency and severity of vivid dreams, sleep disturbance, and gastrointestinal side effects.

  • Bedtime dosing adjustment for sleep effects: If vivid dreams or insomnia persist despite titration, switching LDN to morning dosing can be effective for some individuals, with comparable efficacy reported in clinical practice. Mitigates sleep-architecture disturbance.

  • Baseline liver-function testing: Obtain a CMP (comprehensive metabolic panel, a blood test that includes liver enzymes, kidney function, and electrolytes) before initiation, even though hepatotoxicity at LDN doses is undocumented. Mitigates uncertainty around the boxed warning carried by the 50 mg dose.

  • Communication with all providers, especially before procedures: Inform all healthcare providers (surgeons, dentists, emergency physicians) about LDN use; LDN must be discontinued at least 48-72 hours before any procedure expected to require opioid-based anesthesia or analgesia. Mitigates the risk of inadequate intra- or post-operative pain control.

  • Pharmacy quality verification: Use a PCAB (Pharmacy Compounding Accreditation Board) accredited or USP (United States Pharmacopeia, the standards-setting body for medication quality) <795> compliant compounding pharmacy with verifiable quality testing. Mitigates risks from inconsistent dosing, contamination, or incompatible excipients.

  • Defined trial period with prespecified outcomes: Set a 3-6 month trial with specific functional, biomarker, or symptom endpoints (e.g., pain scale, fatigue scale, hs-CRP (high-sensitivity C-reactive protein, a sensitive marker for low-grade systemic inflammation), sleep quality, NK cell function where available) before continuing indefinitely. Mitigates the risk of indefinite continuation without measurable benefit, particularly in the off-label longevity use case where the within-group versus between-group placebo issue (Ologunowa 2025) is most relevant.

  • Mood monitoring during initiation: Patients with pre-existing mood disorders should self-monitor and report new or worsening symptoms during the first 4-6 weeks. Mitigates the risk of an unrecognized mood-related adverse event being attributed to underlying disease.

Therapeutic Protocol

The most widely used LDN protocol derives from Bernard Bihari’s original clinical practice and has been refined by clinicians including Jarred Younger, Jill Smith, Sajad Zalzala (AgelessRx), and the LDN Research Trust. Two main variants exist: a conventional bedtime regimen prioritizing endorphin rebound, and a morning-dosing regimen prioritizing tolerability — both used by leading practitioners.

  • Standard target dose: 4.5 mg orally once daily. The dose used in most fibromyalgia, Crohn’s, MS (multiple sclerosis), and long COVID trials.

  • Titration schedule: Begin at 1.5 mg nightly for 2 weeks, then 3.0 mg nightly for 2 weeks, then 4.5 mg nightly. Some practitioners start lower (0.5 mg or 1.0 mg), particularly for sensitive patients, and AgelessRx recommends starting at 2.25 mg (half a 4.5 mg tablet) for the first two weeks. Liquid formulations allow finer titration during the introduction phase.

  • Bedtime versus morning dosing: The conventional protocol uses bedtime dosing (typically between 9 PM and midnight) on the rationale that transient opioid receptor blockade during the night produces peak endorphin rebound by morning. Morning dosing is widely used as an alternative when nighttime sleep disturbance is intolerable and is reported by clinicians (including Zalzala/AgelessRx) to provide comparable benefit; no head-to-head trial has formally compared the two.

  • Half-life: Naltrexone has a plasma half-life of approximately 4 hours; the active metabolite 6-beta-naltrexol has a half-life of approximately 12 hours. At LDN doses, the brief receptor occupancy is therapeutically intentional — the goal is transient blockade, not sustained antagonism.

  • Single dose versus split doses: LDN is typically taken once daily as a single dose. Splitting is not the standard approach in trials, since the prevailing mechanism models depend on a brief, concentrated period of receptor blockade followed by rebound.

  • Genetic considerations: CYP2D6 poor metabolizers may experience prolonged blockade and should start at lower doses (0.5-1.0 mg) with slower titration. OPRM1 A118G variant carriers may have altered endorphin signaling, potentially requiring dose optimization. Pharmacogenomic testing is not routine but may be considered for non-responders.

  • Sex-based considerations: No formal sex-based dose adjustment is established. Clinical experience suggests similar dosing for men and women, though women may be slightly more sensitive to sleep-related side effects.

  • Age-related considerations: Adults over 65 should start at the lowest dose (0.5-1.0 mg) due to potentially reduced hepatic clearance and a higher likelihood of polypharmacy. Titration should be slower (increases every 2-3 weeks).

  • Baseline biomarker considerations: Check CMP (including liver function), CBC (complete blood count, a blood test measuring red and white blood cells and platelets), and inflammatory markers (hs-CRP, ESR) before starting LDN to establish baseline values and rule out contraindications.

  • Pre-existing condition considerations: Patients with autoimmune disease on immunosuppressive therapy should initiate LDN only under close specialist supervision, since immune modulation may alter the balance of their treatment. Patients with chronic pain should document baseline pain scores for objective monitoring of response.

Discontinuation & Cycling

  • Lifelong versus short-term use: LDN is generally intended for ongoing, long-term use. Most clinical observations and expert recommendations (Kresser, Zalzala, the LDN Research Trust) indicate that benefits persist as long as LDN is continued and that symptoms often return upon discontinuation. For longevity-oriented users, indefinite use is the typical approach.

  • Withdrawal effects: LDN does not cause physical dependence or a withdrawal syndrome. Discontinuation can be abrupt without medical taper. Individuals may experience a return of pre-existing symptoms (pain, fatigue, inflammation) within days to weeks of stopping, which reflects loss of effect rather than withdrawal.

  • Tapering protocol: Not pharmacologically necessary. Some practitioners reduce by 1.5 mg every few days for patients on long-term LDN to allow a smoother transition, although this practice is empirical rather than evidence-based.

  • Cycling: Cycling (periodic breaks) is not generally recommended, since the proposed endorphin-upregulation and immune-modulating effects appear to require consistent dosing. Some practitioners use brief 2-3 day breaks every few months to address theoretical receptor desensitization, but this is not evidence-based or standard.

  • Pre-procedure discontinuation: LDN should be stopped at least 48-72 hours before any planned surgery or procedure expected to require opioid analgesia, then resumed when opioids have been cleared. This is a discontinuation rather than a cycling consideration, but it is the most clinically relevant interruption pattern in practice.

Sourcing and Quality

  • Prescription requirement: LDN requires a prescription from a licensed healthcare provider; it is not available over the counter. Naltrexone is FDA-approved at 50 mg (oral) and 380 mg (intramuscular), but the low dose (1-5 mg) must be specifically compounded.

  • Compounding pharmacy quality: Look for a pharmacy that is PCAB accredited or otherwise demonstrably compliant with USP (United States Pharmacopeia) Chapter <795> compounding standards, with verifiable quality testing on the finished product. Quality varies meaningfully across compounding pharmacies, and compounded oral capsules are the most common formulation.

  • Formulations: Available as capsules (most common), liquid solutions, sublingual preparations, and rarely transdermal creams. Liquid formulations allow for fine dose titration during the introduction phase. Slow-release capsules are sometimes used to extend the receptor-blockade window, although their pharmacokinetic effect is not formally validated.

  • Excipient considerations: Some compounding pharmacies use fillers containing lactose, gluten, or other potential allergens; calcium carbonate as a filler should be avoided as it has been reported to interfere with naltrexone absorption. Patients with sensitivities should request specific excipient information.

  • Reputable compounding pharmacies and telehealth services: Belmar Pharmacy, Skip’s Pharmacy, and Las Colinas Pharmacy are frequently recommended in the LDN clinical community. AgelessRx and LDN Direct provide telehealth consultations combined with compounding pharmacy fulfillment — note that AgelessRx is a telehealth provider that prescribes and dispenses LDN, a direct commercial interest in positive findings. The LDN Research Trust maintains a directory of LDN-experienced pharmacies and prescribers.

  • Cost: LDN is among the least expensive interventions in the longevity space — typically USD 30-60 for a 90-day supply from a compounding pharmacy, plus a one-time or annual telehealth consultation fee where applicable.

Practical Considerations

  • Time to effect: Most patients report initial effects within 1-4 weeks for sleep quality, energy, and inflammation-driven symptoms. Pain and immune-related benefits often take 8-12 weeks to become apparent. A subset of patients require 3-6 months before experiencing meaningful improvement, and clinicians (including Zalzala) emphasize that finding the individual dose (“Goldilocks dose”) may require multiple titration steps before concluding LDN is ineffective.

  • Common pitfalls: Taking LDN with opioid-containing prescription or OTC products; expecting immediate results; starting at too high a dose rather than titrating gradually; not informing surgeons or anesthesiologists about LDN use before procedures; attempting to split standard 50 mg naltrexone tablets rather than using properly compounded LDN (this results in highly inaccurate dosing); discontinuing prematurely after the initiation flare; and assuming a placebo-controlled benefit when the existing meta-analysis-level evidence is mixed (Ologunowa 2025).

  • Regulatory status: Naltrexone is FDA-approved at 50 mg oral (1984) and 380 mg intramuscular (Vivitrol, 2006) for opioid and alcohol use disorders. LDN (1-5 mg) for all other conditions is off-label use. No specific FDA approval for LDN exists, and none is expected given the long-expired patent and absence of a pharmaceutical sponsor for large registration trials.

  • Cost and accessibility: LDN is affordable (~USD 30-60 per 90 days) but requires a prescription and specialty compounding, which can present barriers in regions with limited compounding-pharmacy availability. Finding a clinician familiar with LDN may be challenging in some areas, although telemedicine services (AgelessRx, LDN Direct) and the LDN Research Trust prescriber directory have improved access.

Interaction with Foundational Habits

  • Sleep: LDN’s most common short-term side effect — vivid dreams and transient insomnia — directly interacts with sleep, especially during the first 1-2 weeks. The proposed mechanism is altered REM sleep architecture from transient opioid blockade. Once adaptation occurs, many users report improved sleep quality, possibly through endorphin-mediated relaxation and reduced pain. Practical considerations: morning dosing is an established alternative; avoid heavy alcohol use which can compound sleep architecture changes.

  • Nutrition: LDN has no specific dietary requirements and can be taken with or without food, although some practitioners prefer empty-stomach administration for more consistent absorption. Direction is largely none. The mechanistic overlap of LDN with anti-inflammatory dietary patterns (Mediterranean, low-glycemic, polyphenol-rich) is potentially additive but has not been formally studied. No documented nutrient depletions are associated with LDN.

  • Exercise: Direction is potentiating in chronic-pain populations: by reducing pain and inflammation, LDN may enable more consistent exercise, particularly Zone 2 (a moderate-intensity aerobic exercise zone where the body relies primarily on fat oxidation) cardiovascular and resistance training. There is no evidence that LDN blunts exercise adaptations the way some high-dose antioxidants may. The short plasma half-life makes peri-workout timing largely irrelevant.

  • Stress management: LDN’s proposed endorphin-upregulating mechanism may provide a modest buffer against stress through enhanced endogenous opioid tone. Direction is potentiating in concept, although direct cortisol or autonomic data are sparse. LDN does not directly modulate cortisol (the body’s primary stress hormone), but its anti-inflammatory effects may indirectly benefit the HPA axis (hypothalamic-pituitary-adrenal axis, the central stress response system) by reducing inflammation-driven cortisol dysregulation. Practical consideration: LDN does not substitute for sleep, nutrition, or contemplative practice as foundational stress-management interventions.

Monitoring Protocol & Defining Success

Baseline assessment should establish hepatic safety, characterize the inflammatory state at which the user is starting, and capture functional or symptom anchors against which response can be measured. Off-label longevity use should adopt the same monitoring rigor as off-label disease use.

  • Baseline labs and tests: CMP (including liver function and creatinine); CBC with differential; hs-CRP; ESR; lipid panel; HbA1c (glycated hemoglobin, a 3-month average of blood glucose); and a documented opioid-use history with urine drug screen where appropriate. Functional anchors such as a validated pain scale, fatigue scale, sleep questionnaire, and symptom diary should be recorded before initiation.

  • Ongoing monitoring cadence: Repeat liver function, CBC, hs-CRP, and ESR at 3 months and then every 6-12 months. Functional and symptom anchors should be reassessed monthly for the first 3 months and then quarterly during the first year.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
ALT 10-25 U/L Monitor liver safety Alanine aminotransferase, a liver enzyme used to assess liver health. Conventional reference up to 40 U/L; functional medicine targets a tighter range. Naltrexone hepatotoxicity warning applies primarily to 50 mg+ doses. Fasting not required
AST 10-25 U/L Monitor liver safety Aspartate aminotransferase, another liver enzyme. Conventional reference up to 40 U/L. Pair with ALT for hepatic assessment
GGT <25 U/L (women); <35 U/L (men) Early marker of subclinical hepatic stress Gamma-glutamyl transferase, a liver enzyme sensitive to alcohol and drug effects. Conventional reference up to 65 U/L; more sensitive than ALT/AST for early hepatic adaptation
hs-CRP <1.0 mg/L Track systemic inflammation; expected to fall if LDN’s anti-inflammatory mechanism is active Conventional reference <3.0 mg/L; functional medicine target <1.0 mg/L; ideal <0.5 mg/L. Fasting not required
ESR <10 mm/hr (men); <15 mm/hr (women) Secondary inflammation marker Conventional reference <20 mm/hr; documented to improve in LDN fibromyalgia trials
CBC with differential Within standard ranges, with attention to lymphocyte count Monitor immune-cell populations under modulation Track lymphocyte and NK cell counts where the longevity rationale rests on immune effects. Fasting not required
HbA1c <5.4% Inflammation and glucose regulation are intertwined; tracks an aging-relevant metabolic marker Conventional optimal up to 5.6%; functional medicine target <5.4%. Fasting not required
Beta-endorphin (when available) No established optimal range Direct readout of endorphin upregulation, the proposed downstream effect of LDN Specialized test; not widely available or reimbursed. Best drawn in the morning; primarily of research interest
Pain or fatigue scale (e.g., Brief Pain Inventory, Chalder Fatigue Scale) Individualized Track the symptom domain the user is targeting Pre-specify the instrument and the threshold for “meaningful improvement” before initiation

Qualitative markers to track:

  • Pain intensity and frequency (where applicable)
  • Sleep quality and morning refreshment
  • Energy and exercise tolerance
  • Cognitive clarity and mental endurance
  • Mood stability
  • Frequency of infections or autoimmune flares

Emerging Research

  • LIFT: Life Improvement Trial (NCT06366724): A Phase 2, randomized, placebo-controlled trial (n=160) of LDN for ME/CFS and long COVID, with a primary completion date of September 2026. Will provide the first randomized evidence in the post-viral fatigue domain where LDN is currently most heavily prescribed off-label.

  • Combination Gerotherapeutic Interventions for Healthspan Improvement (NCT07475546): A small Phase 3 study (n=30) investigating LDN as part of a multi-intervention longevity protocol with healthspan-related endpoints and aging biomarkers, sponsored by AgelessRx — note that AgelessRx is a telehealth provider that prescribes and dispenses LDN, a direct commercial interest in positive findings. The first formal clinical study of LDN within an explicit gerotherapeutic stack.

  • Low-Dose Naltrexone for ME/CFS dose-finding (NCT07285473): A Phase 2 dose-finding study (n=75) aimed at identifying optimal LDN dosing in ME/CFS. Will help resolve persistent uncertainty about whether 4.5 mg is the right target dose for post-viral fatigue.

  • Low Dose Naltrexone (LDN) for Management of Fatigue in Prostate Cancer Patients on Androgen Deprivation Therapy (NCT07224009): A Phase 2 trial (n=60) of LDN for ADT (androgen deprivation therapy, a hormonal treatment for prostate cancer)-related fatigue. Will inform whether LDN’s anti-inflammatory and endorphin-related effects translate to oncology-supportive care.

  • Low Dose Naltrexone for Central Neuropathic Pain in Spinal Cord Injury (NCT06723561): A Phase 2 trial of LDN for central neuropathic pain after spinal cord injury. Extends the chronic-pain evidence base beyond fibromyalgia.

  • Cost-utility and Physiological Effects of LDN in Patients with Fibromyalgia (NCT04739995): A Phase 4 randomized trial (n=99) examining cost-utility and physiological outcomes; results pending. May be pivotal in resolving the placebo-versus-active-effect uncertainty raised by the 2025 fibromyalgia meta-analyses.

  • Restored TRPM3 ion channel function in NK cells: Sasso et al., 2025 demonstrated that LDN restores TRPM3 ion-channel function in NK cells from long COVID patients to that of healthy controls — a concrete cellular mechanism that may anchor the long COVID and ME/CFS use case.

  • Lifespan extension in C. elegans: Li et al., 2024 showed dose-dependent healthspan and lifespan extension at low (2.5-5 micromolar) but not high naltrexone concentrations via SKN-1/NRF2 activation, providing the principal published preclinical evidence linking LDN to canonical longevity pathways.

  • Bone mineral density case report: Britton et al., 2025 reported a 15.9% increase in lumbar spine bone mineral density over two years in a 52-year-old woman taking rapamycin and subsequently LDN, opening (but in no way confirming) a hypothesis around bone-density effects of combination gerotherapeutic regimens.

  • Long COVID trajectory analysis: Jagannathan et al., 2025 found that worsening symptom-trajectory groups in the STOP-PASC trial had a higher proportion of LDN users — most parsimoniously explained as confounding-by-indication, but underscoring the need for randomized rather than observational evidence in this population.

  • Fibromyalgia meta-analysis with trial sequential analysis: Vatvani et al., 2024 and the 2026 corrigendum provide the most statistically rigorous meta-analytic estimate to date for the LDN-versus-placebo pain-score difference in fibromyalgia.

  • Areas of future research that could change current understanding: randomized data on long COVID and ME/CFS (LIFT trial); whether the C. elegans SKN-1/NRF2 mechanism described in Li et al., 2024 translates to mammals and humans; whether any aging biomarker (epigenetic clock, GlycanAge, biological-age panel) responds to LDN at the population level; whether combination with rapamycin or other gerotherapeutics is additive, neutral, or antagonistic, building on the case observation by Britton et al., 2025; pharmacogenomic predictors of response (OPRM1, CYP2D6); and adequately powered head-to-head comparisons of bedtime versus morning dosing relative to the chronic-pain mechanism framework outlined in Younger et al., 2014.

Conclusion

Low-dose naltrexone is an off-label use of a long-marketed opioid antagonist at roughly one-tenth of its standard dose, where it appears to act less as a classic opioid blocker and more as a modulator of glial cells, inflammation, and endogenous opioid tone. The strongest controlled evidence is in chronic pain — particularly fibromyalgia — and Crohn’s disease, where small trials and pooled analyses suggest a real but modest effect against placebo, though one recent analysis found the between-group difference non-significant. Use in long COVID, multiple sclerosis, and complex regional pain syndrome rests on mechanistic plausibility and small studies rather than randomized data.

The safety profile is favorable across the studied dose range: pooled data show no excess of serious adverse events, and the most common issues are vivid dreams, transient sleep disturbance, mild gastrointestinal upset, and an initiation flare. The single most important acute concern is the absolute contraindication with opioid agonists, which can produce severe precipitated withdrawal.

For the longevity case, the evidence is preliminary and partly emerges from clinician-investigators with commercial ties to LDN-prescribing telehealth services. A worm lifespan study and case reports suggest alignment with canonical aging pathways, but no human study has used aging biomarkers or longevity endpoints as primary outcomes. A long safety record, very low cost, and a plausible anti-inflammatory profile keep it in active conversation, while the limited and mixed direct evidence for healthspan benefit in non-clinical populations leaves its place in a longevity stack uncertain.

Top - Benefits - Risks - Protocol